Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Phorbol esters such as 12‐O‐tetradecanoylphorbol‐13‐acetate (TPA) inhibit the growth of A549 human lung carcinoma cells at non‐toxic concentrations, whereas 1‐oleoyl‐2‐acetylglycerol and 1,2‐dioctanoylglycerol, synthetic analogues of the physiological ligands of protein kinase C (PKC), do not. Experiments were conducted to test the hypothesis that other activators of PKC are capable of interfering with A549 cell growth. The non‐phorboid tumour promotor mezerein mimicked the growth‐inhibitory effect of TPA in that it arrested growth for 5 days, after which cells proliferated again in the continued presence of the agent. TPA was 20 times more potent as a growth inhibitor than was mezerein. Bryostatin 1 at 10 nM and bryostatin 2 at 100 nM also arrested A549 cell growth and inhibited DNA replication as measured by incorporation of [methyl‐3 H]‐thymidine into cells. Inhibition of DNA synthesis to between 90 and 75% of control values developed during the first hour of incubation of the cells with TPA, mezerein or the bryostatins. The extent of inhibition changed little during the subsequent 5 hr of incubation, after which it increased further to reach maximal values within 12 hr. At concentrations above those which caused maximal growth inhibition, the bryostatins abolished both their own inhibition of DNA synthesis and the anti‐replicative effect of TPA and mezerein. The results show that activators of PKC other than phorbol esters are capable of inhibiting the growth of A549 cells. The bryostatins not only interfere with A549 cell growth but can also counter the growth‐inhibitory effect of PKC activators, presumably via interaction with a target separate from the phorbol ester receptor site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hennings, H., Blumberg, P. M., Pettit, G. R., Herald, C. L., Shores, R., & Yuspa, S. H. (1987) · Carcinogenesis · doi:10.1093/carcin/8.9.1343 · Cited by 230
Cited by
Review of survival analyses published in cancer journals
Altman, D., De Stavola, B., Love, S., & Stepniewska, K. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.364 · Cited by 438
Bryostatin-1: A novel PKC inhibitor in clinical development
Kortmansky, J., & Schwartz, G. K. (2003) · Cancer Investigation · doi:10.1081/cnv-120025095 · Cited by 183
Phorbol ester-stimulated phosphorylation of PU.1: association with leukemic cell growth inhibition
Carey, J., Posekany, K., deVente, J., Pettit, G., & Ways, D. (1996) · Blood · doi:10.1182/blood.v87.10.4316.bloodjournal87104316 · Cited by 58
Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer
Sadeghi, M. M., Salama, M. F., & Hannun, Y. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115527 · Cited by 31
Metadata
- Authors
- Dale, I. L., & Gescher, A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1989-01-15
- Volume
- 43
- Issue
- 1
- Pages
- 158-163
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1989859193
- Cited by
- 59
- References
- 1
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.